ArriVent BioPharma, Inc. (AVBP) Form 8-K — Aug 12, 2026
ArriVent BioPharma entered a collaboration and license agreement granting Shanghai Allist Pharmaceuticals exclusive rights to develop and commercialize ARR-002, its MUC16/NaPi2b-targeted antibody-drug conjugate, in Greater China. ArriVent may receive payments totaling as much as $80.6 million in upfront and milestone payments plus tiered royalties in the mid-single digit to low double-digit percentages, while retaining all rights to ARR-002 outside the region. Alongside the deal, ArriVent reported second quarter 2026 results with cash and investments of $373.1 million as of June 30, 2026, expected to fund operations into 2028.
Key figures
- Eps
- -$1.05 (Q2 2026 basic and diluted)
- Net Income
- -$49.9 million Q2 2026; -$93.2 million for six months ended June 30, 2026
- Cash Position
- $373.1 million (cash and investments as of June 30, 2026)
- Deal Value Usd
- $80.6 million (maximum potential upfront plus milestone payments under Allist license)
- Shares Outstanding
- 48319591
- Cash runway
- into 2028
- Royalty rate
- mid-single digit to low double-digit percentages on annual net sales in Licensed Territory
- Total assets
- $394.7 million
- Furvent enrollment
- 398
- Licensed territory
- Greater China (mainland China, Hong Kong, Macau, Taiwan)
- Q2 2026 ga expense
- $10.4 million (vs $5.9 million Q2 2025)
- Q2 2026 rd expense
- $42.3 million (vs $27.7 million Q2 2025)
- Six month ga expense
- $18.8 million (vs $11.4 million prior year)
- Six month rd expense
- $80.0 million (vs $89.0 million prior year)
- Net cash used in operations 6m 2026
- $81.5 million
Price after filing
Close on the filing date to close N calendar days later (from $31.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.